Effects of anti-TNF therapy on ophtalmological complications in children with rheumatic diseases
© Frkovic et al; licensee BioMed Central Ltd. 2014
Published: 17 September 2014
Biologics started a new era in treatment of different aspects of rheumatic disases. Authors present the effects of anti-TNF therapy on ophtalmological complications in their patients with juvenile idiopathic artritis (JIA), juvenile dermatomiositis (JDM) and sarcoidosis.
To investigate therapeutical sucess of anti-TNF therapy on ophtalmological complications in children with rheumatic diseases.
Retrospective chart rewiev of all rheumatic patients with ophtalmological complications treated with anti-TNF therapy at Division of Paediatric Rheumatology and Immunology, University Hospital Centre Zagreb, during 2009. – 2013. period.
Among 54 children treated with anti-TNF therapy at our Division during 2009. – 2013. period, 10 were detected with ophtalmologycal complications (8 girls, 2 boys), 8 with JIA, 1 with JDM and 1 with sarcoidosis. Nine patients had chronic uveitis (JIA, sarcoidosis) and 1 had …cotton wool“ retinal lesions accompanied with bilateral papilar oedema (JDM). Avarage time between the begining of disease and start of anti-TNF therapy was 2.9 years (28 days – 9 years). Initial anti-TNF therapy was adalimumab in 5 cases (4 JIA, 1 sarcoidosis), etanercept in 4 cases (JIA) and infliximab in 1 case (JDM). During therapy, etanercept was changed to adalimumab in 2 cases, due to inefficacy on uveitis. Adalimumab was partially effective in 1 case (sarcoidosis). Infliximab, applied in patient with JDM and …cotton wool“ retinal lesions accompanied with bilateral papilar oedema, led to fast and complete recovery of eye changes and other aspects of the disease.
Anti-TNF therapy was successfull in 90 % of our cases. To our opinion, anti-TNF therapy should be early introduced in rheumatic patients with severe ophtalmological complications.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.